Press Resease

Insulin Delivery Devices Market - Global Industry Analysis

Insulin Delivery Devices Market by Product (Insulin Pens, Insulin Syringes, and Insulin Pumps) and Distribution Channel (Diabetes Clinics and Centers, Retail Pharmacy, Hospital Pharmacy, and Online Sales): Global Industry Perspective, Comprehensive Analysis, and Forecast, 2017–2024

Published Date: 29-Nov-2018 Category: Healthcare Report Format : PDF Pages: 110 Report Code: ZMR-3571 Status : Published

Global insulin delivery devices market expected to generate revenue of around USD 18.5 billion by 2024, growing at a CAGR of around 8.9% between 2018 and 2024. Insulin has to be injected under the skin into the fatty tissue. A wide variety of devices are employed for the supply of insulin, including pens, syringes, injectors, and pumps.

Description

The report covers forecast and analysis for the insulin delivery devices market on a global and regional level. The study provides historical data from 2015 to 2017 along with a forecast from 2018 to 2024 based on revenue (USD Billion). The study includes drivers and restraints for the insulin delivery devices market along with the impact they have on the demand over the forecast period. Additionally, the report includes the study of opportunities available in the insulin delivery devices market on a global as well as regional level.

In order to give the users of this report a comprehensive view of the insulin delivery devices market, we have included a competitive landscape and an analysis of Porter’s Five Forces model for the market. The study encompasses a market attractiveness analysis, wherein Product segment is benchmarked based on their market size, growth rate, and general attractiveness.

Global Insulin Delivery Devices Market

The report provides company market share analysis in order to give a broader overview of the key players in the insulin delivery devices market. In addition, the report also covers key strategic developments of the market including acquisitions & mergers, new product launch, agreements, partnerships, collaborations & joint ventures, research& development, and regional expansion of major participants involved in the insulin delivery devices market on a global and regional basis. 

The study provides a decisive view on the insulin delivery devices market by segmenting the market based on product, distribution channel, and region. The segments have been analyzed based on present and future trends and the market is estimated from 2018 to 2024. Based on the product, the insulin delivery devices market has been segmented into insulin pens, insulin syringes, and insulin pumps. Insulin pens hold the majority share of the product segment, due to increased demand for improved diabetes management and minimally invasive property of pens. The distribution channel segment has been segmented into diabetes clinics and centers, retail pharmacy, hospital pharmacy, and online sales.

The regional segmentation includes the current and forecast demand for North America, Europe, Asia Pacific, Latin America, and the Middle East and Africa with its further bifurcation into major countries including the U.S. Canada, Germany, France, UK, China, Japan, India, and Brazil. This segmentation includes demand for insulin delivery devices based on individual segments and types in all regions and countries.

The report also includes detailed profiles of end players, such as Eli Lilly and Company, Medtronic plc., B. Braun Melsungen AG, Sanofi S.A., Novo Nordisk A/S, F. Hoffmann-La Roche Ltd., Biocon Ltd., Becton, Dickinson and Company, Valeritas, Inc., MannKind Corporation, and Insulet Corporation, among others.

This report segments the global insulin delivery devices market as follows:

Global Insulin Delivery Devices Market: By Product

  • Insulin Pens
  • Insulin Syringes
  • Insulin Pumps

Global Insulin Delivery Devices Market: By Distribution Channel

  • Diabetes Clinics and Centers
  • Retail Pharmacy
  • Hospital Pharmacy
  • Online Sales

Global Insulin Delivery Devices Market: By Region

  • North America
    • The U.S.
  • Europe
    • UK
    • France
    • Germany
  • Asia Pacific
    • China
    • Japan
    • India
  • Latin America
    • Brazil
  • Middle East and Africa

Table Of Content

  • Chapter 1. Introduction
    • 1.1. Report description and scope
    • 1.2. Research scope
    • 1.3. Research methodology
      • 1.3.1. Market research process
      • 1.3.2. Market research methodology
  •  
  • Chapter 2. Executive Summary
    • 2.1. Global Insulin Delivery Devices market, 2017-2024 (USD Billion)
    • 2.2. Global Insulin Delivery Devices market: Snapshot
  •  
  • Chapter 3. Insulin Delivery Devices Market - Dynamics
    • 3.1. Introduction
    • 3.2. Market drivers
      • 3.2.1. Global Insulin Delivery Devices market drivers: Impact analysis
      • 3.2.2. The rise in chronic diseases associated with diabetes
      • 3.2.3. Increase in demand for insulin transmission products
    • 3.3. Market Restraints
      • 3.3.1. The high cost of insulin devices
      • 3.3.2. The discrepancy in insulin uptake adherence
    • 3.4. Opportunities
      • 3.4.1. Efforts were taken by the various government and non-government organizations to increase awareness regarding insulin devices
    • 3.5. Porter's five forces analysis
      • 3.5.1. Bargaining power of suppliers
      • 3.5.2. Bargaining power of buyers
      • 3.5.3. The threat from new entrants
      • 3.5.4. The threat from new substitutes
      • 3.5.5. Degree of competition
    • 3.6. Market attractiveness analysis
      • 3.6.1. Market attractiveness analysis, by product segment
      • 3.6.2. Market attractiveness analysis, by distribution channel
  •  
  • Chapter 4. Global Insulin Delivery Devices Market - Competitive Landscape
    • 4.1. Company Market Share Analysis
      • 4.1.1. Global Insulin Delivery Devices market: company market share, 2017
    • 4.2. Strategic Development
      • 4.2.1. Acquisitions & Mergers
      • 4.2.2. New Product Launch
      • 4.2.3. Agreements, Partnerships, Collaborations and Joint Ventures
      • 4.2.4. Research and Development, Regional Expansion
  •  
  • Chapter 5. Global Insulin Delivery Devices Market - Product Segment Analysis
    • 5.1. Global Insulin Delivery Devices market: Product overview
      • 5.1.1. Global Insulin Delivery Devices market revenue share, by Product, 2017 and 2024
    • 5.2. Insulin Pens
      • 5.2.1. Global Insulin Delivery Devices market for Insulin Pens, 2017 - 2024(USD Billion)
    • 5.3. Insulin Syringes
      • 5.3.1. Global Insulin Delivery Devices market for Insulin Syringes, 2017 - 2024(USD Billion)
    • 5.4. Insulin Pumps
      • 5.4.1. Global Insulin Delivery Devices market for Insulin Pumps, 2017 - 2024 (USD Billion)
  •  
  • Chapter 6. Global Insulin Delivery Devices Market - Distribution Channel Segment Analysis
    • 6.1. Global Insulin Delivery Devices Market: Distribution Channel overview
      • 6.1.1. Global Insulin Delivery Devices market revenue share, by Distribution Channel, 2017 and 2024
    • 6.2. Diabetes Clinics and Centers
      • 6.2.1. Global Insulin Delivery Devices market for Diabetes Clinics and Centers, 2017 - 2024 (USD Billion)
    • 6.3. Retail Pharmacy
      • 6.3.1. Global Insulin Delivery Devices market for Retail Pharmacy, 2017 - 2024 (USD Billion)
    • 6.4. Hospital Pharmacy
      • 6.4.1. Global Insulin Delivery Devices market for Hospital Pharmacy, 2017 - 2024 (USD Billion)
    • 6.5. Online Sales
      • 6.5.1. Global Insulin Delivery Devices market for Online Sales, 2017 - 2024 (USD Billion)
  •  
  • Chapter 7. Global Insulin Delivery Devices Market - Regional Segment Analysis
    • 7.1. Global Insulin Delivery Devices market: Regional overview
      • 7.1.1. Global Insulin Delivery Devices market revenue share, by region, 2017 and 2024
    • 7.2. North America
      • 7.2.1. North America Insulin Delivery Devices market revenue, by Product, 2017 - 2024(USD Billion)
      • 7.2.2. North America Insulin Delivery Devices market revenue, by Distribution Channel, 2017 - 2024 (USD Billion)
      • 7.2.3. The U.S.
        • 7.2.3.1. The U.S. Insulin Delivery Devices market revenue, by Product, 2017 - 2024(USD Billion)
        • 7.2.3.2. The U.S. Insulin Delivery Devices market revenue, by Distribution Channel, 2017 - 2024 (USD Billion)
      • 7.2.4. Canada
        • 7.2.4.1. Canada Insulin Delivery Devices market revenue, by Product, 2017 - 2024 (USD Billion)
        • 7.2.4.2. Canada Insulin Delivery Devices market revenue, by Distribution Channel, 2017 - 2024 (USD Billion)
      • 7.2.5. Rest of North America
        • 7.2.5.1. Rest of North America Insulin Delivery Devices market revenue, by Product, 2017 - 2024(USD Billion)
        • 7.2.5.2. Rest of North America Insulin Delivery Devices market revenue, by Distribution Channel, 2017 - 2024 (USD Billion)
    • 7.3. Europe
      • 7.3.1. Europe Insulin Delivery Devices market revenue, by Product, 2017 - 2024(USD Billion)
      • 7.3.2. Europe Insulin Delivery Devices market revenue, by Distribution Channel, 2017 - 2024 (USD Billion)
      • 7.3.3. Germany
        • 7.3.3.1. Germany Insulin Delivery Devices market revenue, by Product, 2017 - 2024(USD Billion)
        • 7.3.3.2. Germany Insulin Delivery Devices market revenue, by Distribution Channel, 2017 - 2024 (USD Billion)
      • 7.3.4. U.K.
        • 7.3.4.1. U.K. Insulin Delivery Devices market revenue, by Product, 2017 - 2024(USD Billion)
        • 7.3.4.2. U.K. Insulin Delivery Devices market revenue, by Distribution Channel, 2017 - 2024 (USD Billion)
        • 7.3.5. France
        • 7.3.5.1. France Insulin Delivery Devices market revenue, by Product, 2017 - 2024(USD Billion)
        • 7.3.5.2. France Insulin Delivery Devices market revenue, by Distribution Channel, 2017 - 2024 (USD Billion)
      • 7.3.6. Italy
        • 7.3.6.1. Italy Insulin Delivery Devices market revenue, by Product, 2017 - 2024 (USD Billion)
        • 7.3.6.2. Italy Insulin Delivery Devices market revenue, by Distribution Channel, 2017 - 2024 (USD Billion)
      • 7.3.7. Spain
        • 7.3.7.1. Spain Insulin Delivery Devices market revenue, by Product, 2017 - 2024 (USD Billion)
        • 7.3.7.2. Spain Insulin Delivery Devices market revenue, by Distribution Channel, 2017 - 2024 (USD Billion)
      • 7.3.8. Russia
        • 7.3.8.1. Russia Insulin Delivery Devices market revenue, by Product, 2017 - 2024 (USD Billion)
        • 7.3.8.2. Russia Insulin Delivery Devices market revenue, by Distribution Channel, 2017 - 2024 (USD Billion)
      • 7.3.9. Rest of Europe
        • 7.3.9.1. Rest of Europe Insulin Delivery Devices market revenue, by Product, 2017 - 2024(USD Billion)
        • 7.3.9.2. Rest of Europe Insulin Delivery Devices market revenue, by Distribution Channel, 2017 - 2024 (USD Billion)
    • 7.4. Asia Pacific
      • 7.4.1. Asia Pacific Insulin Delivery Devices market revenue, by Product, 2017 - 2024(USD Billion)
      • 7.4.2. Asia Pacific Insulin Delivery Devices market revenue, by Distribution Channel, 2017 - 2024 (USD Billion)
      • 7.4.3. China
        • 7.4.3.1. China Insulin Delivery Devices market revenue, by Product, 2017 - 2024(USD Billion)
        • 7.4.3.2. China Insulin Delivery Devices market revenue, by Distribution Channel, 2017 - 2024 (USD Billion)
      • 7.4.4. Japan
        • 7.4.4.1. Japan Insulin Delivery Devices market revenue, by Product, 2017 - 2024(USD Billion)
        • 7.4.4.2. Japan Insulin Delivery Devices market revenue, by Distribution Channel, 2017 - 2024 (USD Billion)
      • 7.4.5. India
        • 7.4.5.1. India Insulin Delivery Devices market revenue, by Product, 2017 - 2024(USD Billion)
        • 7.4.5.2. India Insulin Delivery Devices market revenue, by Distribution Channel, 2017 - 2024 (USD Billion)
      • 7.4.6. Australia
        • 7.4.6.1. Australia Insulin Delivery Devices market revenue, by Product, 2017 - 2024 (USD Billion)
        • 7.4.6.2. Australia Insulin Delivery Devices market revenue, by Distribution Channel, 2017 - 2024 (USD Billion)
      • 7.4.7. Rest of Asia Pacific
        • 7.4.7.1. Rest of Asia Pacific Insulin Delivery Devices market revenue, by Product, 2017 - 2024(USD Billion)
        • 7.4.7.2. Rest of Asia Pacific Insulin Delivery Devices market revenue, by Distribution Channel, 2017 - 2024 (USD Billion)
    • 7.5. Latin America
      • 7.5.1. Latin America Insulin Delivery Devices market revenue, by Product, 2017 - 2024(USD Billion)
      • 7.5.2. Latin America Insulin Delivery Devices market revenue, by Distribution Channel, 2017 - 2024 (USD Billion)
      • 7.5.3. Brazil
        • 7.5.3.1. Brazil Insulin Delivery Devices market revenue, by Product, 2017 - 2024(USD Billion)
        • 7.5.3.2. Brazil Insulin Delivery Devices market revenue, by Distribution Channel, 2017 - 2024 (USD Billion)
      • 7.5.4. Mexico
        • 7.5.4.1. Mexico Insulin Delivery Devices market revenue, by Product, 2017 - 2024 (USD Billion)
        • 7.5.4.2. Mexico Insulin Delivery Devices market revenue, by Distribution Channel, 2017 - 2024 (USD Billion)
      • 7.5.5. Argentina
        • 7.5.5.1. Argentina Insulin Delivery Devices market revenue, by Product, 2017 - 2024 (USD Billion)
        • 7.5.5.2. Argentina Insulin Delivery Devices market revenue, by Distribution Channel, 2017 - 2024 (USD Billion)
      • 7.5.6. Rest of Latin America
        • 7.5.6.1. Rest of Latin America Insulin Delivery Devices market revenue, by Product, 2017 - 2024(USD Billion)
        • 7.5.6.2. Rest of Latin America Insulin Delivery Devices market revenue, by Distribution Channel, 2017 - 2024 (USD Billion)
    • 7.6. Middle East and Africa
      • 7.6.1. The Middle East and Africa Insulin Delivery Devices market revenue, by Product, 2017 - 2024(USD Billion)
      • 7.6.2. The Middle East and Africa Insulin Delivery Devices market revenue, by Distribution Channel, 2017 - 2024 (USD Billion)
      • 7.6.3. Saudi Arabia
        • 7.6.3.1. Saudi Arabia Insulin Delivery Devices market revenue, by Product, 2017 - 2024 (USD Billion)
        • 7.6.3.2. Saudi Arabia Insulin Delivery Devices market revenue, by Distribution Channel, 2017 - 2024 (USD Billion)
      • 7.6.4. UAE
        • 7.6.4.1. UAE Insulin Delivery Devices market revenue, by Product, 2017 - 2024 (USD Billion)
        • 7.6.4.2. UAE Insulin Delivery Devices market revenue, by Distribution Channel, 2017 - 2024 (USD Billion)
      • 7.6.5. South Africa
        • 7.6.5.1. South Africa Insulin Delivery Devices market revenue, by Product, 2017 - 2024 (USD Billion)
        • 7.6.5.2. South Africa Insulin Delivery Devices market revenue, by Distribution Channel, 2017 - 2024 (USD Billion)
      • 7.6.6. Qatar
        • 7.6.6.1. Qatar Insulin Delivery Devices market revenue, by Product, 2017 - 2024 (USD Billion)
        • 7.6.6.2. Qatar Insulin Delivery Devices market revenue, by Distribution Channel, 2017 - 2024 (USD Billion)
      • 7.6.7. Rest of the Middle East and Africa
        • 7.6.7.1. Rest of the Middle East and Africa Insulin Delivery Devices market revenue, by Product, 2017 - 2024 (USD Billion)
        • 7.6.7.2. Rest of the Middle East and Africa Insulin Delivery Devices market revenue, by Distribution Channel, 2017 - 2024 (USD Billion)
  •  
  • Chapter 8. Company Profile
    • 8.1. Eli Lilly and Company
      • 8.1.1. Overview
      • 8.1.2. Financials
      • 8.1.3. Therapy portfolio
      • 8.1.4. Business strategy
      • 8.1.5. Recent developments
    • 8.2. Medtronic plc.
      • 8.2.1. Overview
      • 8.2.2. Financials
      • 8.2.3. Therapy portfolio
      • 8.2.4. Business strategy
      • 8.2.5. Recent developments
    • 8.3. B. Braun Melsungen AG
      • 8.3.1. Overview
      • 8.3.2. Financials
      • 8.3.3. Therapy portfolio
      • 8.3.4. Business strategy
      • 8.3.5. Recent developments
    • 8.4. Sanofi S.A.
      • 8.4.1. Overview
      • 8.4.2. Financials
      • 8.4.3. Therapy portfolio
      • 8.4.4. Business strategy
      • 8.4.5. Recent developments
    • 8.5. Bayer AG
      • 8.5.1. Overview
      • 8.5.2. Financials
      • 8.5.3. Therapy portfolio
      • 8.5.4. Business strategy
      • 8.5.5. Recent developments
    • 8.6. Novo Nordisk A/S
      • 8.6.1. Overview
      • 8.6.2. Financials
      • 8.6.3. Therapy portfolio
      • 8.6.4. Business strategy
      • 8.6.5. Recent developments
    • 8.7. F. Hoffmann-La Roche Ltd.
      • 8.7.1. Overview
      • 8.7.2. Financials
      • 8.7.3. Therapy portfolio
      • 8.7.4. Business strategy
      • 8.7.5. Recent developments
    • 8.8. Biocon Ltd.
      • 8.8.1. Overview
      • 8.8.2. Financials
      • 8.8.3. Therapy portfolio
      • 8.8.4. Business strategy
      • 8.8.5. Recent developments
    • 8.9. Becton, Dickinson and Company
      • 8.9.1. Overview
      • 8.9.2. Financials
      • 8.9.3. Therapy portfolio
      • 8.9.4. Business strategy
      • 8.9.5. Recent developments
    • 8.10. Valeritas, Inc.
      • 8.10.1. Overview
      • 8.10.2. Financials
      • 8.10.3. Therapy portfolio
      • 8.10.4. Business strategy
      • 8.10.5. Recent developments
    • 8.11. MannKind Corporation
      • 8.11.1. Overview
      • 8.11.2. Financials
      • 8.11.3. Therapy portfolio
      • 8.11.4. Business strategy
      • 8.11.5. Recent developments
    • 8.12. Insulet Corporation
      • 8.12.1. Overview
      • 8.12.2. Financials
      • 8.12.3. Therapy portfolio
      • 8.12.4. Business strategy
      • 8.12.5. Recent developments

Methodology

Free Analysis

Insulin, a peptide hormone, is manufactured by beta cells present in the pancreatic islets. It is regarded as the major anabolic hormone of the human body. It coordinates the metabolism of proteins, fats, and carbohydrates by stimulating the assimilation of carbohydrates, majorly glucose into fat, liver, and skeletal muscle cells from the blood. Insulin helps in maintaining the blood sugar level. If a person’s body is incapable of producing enough insulin or the cells are impervious to insulin effects, then that person might become hyperglycemic (elevated blood sugar).

Diabetes affects the body’s capability to process blood sugar. Gestational diabetes, type 1, and type 2 are three major diabetes types. Gestational diabetes occurs in females during pregnancy. Type 1 diabetes is developed when the body is incapable of producing insulin. People with diabetes type 1 are completely dependent on insulin and have to intake artificial insulin on a daily basis. Type 2 diabetes affects the body’s utilization of insulin. It is the most prevalent diabetes type. Multiple studies have found obesity to be the major cause of type 2 diabetes. Insulin is an essential part of therapy for patients with types 1 and 2 diabetes. Multiple devices are used for insulin delivery, such as including pens, syringes, injectors, and pumps.

Global Insulin Delivery Devices Market

As per the WHO, the diabetic population has grown from 108 million adults in 1980 to approximately 422 million adults in 2014. Furthermore, diabetic prevalence globally has doubled from 4.7% in 1980 to around 8.5% in 2014. According to the latest statistics for the United States of 2017, approximately 30 million people have diabetes, out of which around 24 million patients were diagnosed and around 6 million patients continue to be undiagnosed.

Rise in chronic diseases associated with diabetes, injury recovery time, increase in the demand for insulin transmission products, and growing awareness regarding insulin delivery products are likely to act as major growth driving factors in the global insulin delivery devices market. Furthermore, increase in the occurrences of pediatric and geriatric diabetes, various advantages offered by minimally invasive treatment options, such as pumps, improved functioning and design of insulin devices, unhealthy eating habits, lack of active lifestyle, increasing healthcare expenditure, and increasing research and development activities, are also projected to propel this market’s growth. Efforts taken by various governments and non-government organizations to increase awareness regarding insulin devices and rapid advancements in the technology are anticipated to act as opportunities for the players operating in the insulin delivery devices market. However, the high cost of insulin devices, the discrepancy in insulin uptake adherence, needle-phobia of many individuals, resistance to self-injection, inadequate per capita expenditure on diabetes, and the absence of insurance and reimbursement in developing regions might restrict the global insulin delivery devices market.

The global insulin delivery devices market is segmented based on product and distribution channel. By product, the insulin delivery devices market is classified into insulin pens, insulin syringes, and insulin pumps. Insulin pens hold the majority market share, due to increased demand for improved diabetes management and minimally invasive property of pens. The distribution channel segment includes diabetes clinics and centers, retail pharmacy, hospital pharmacy, and online sales.

North America is likely to be the leading region during the forecast time period. Increasing prevalence of diabetes mellitus, growing espousal of an unhealthy diet are to boost this regional market’s growth. Europe is likely to display substantial growth in the near future, due to increasing healthcare expenditure and rising awareness regarding several diabetic complications. The Asia Pacific is likely to propagate at a speedy rate over the forecast time period. Increasing geriatric population, growing pediatric diabetic population, multiple efforts taken by governments and non-government organizations are likely to boost this market’s growth. Latin America is likely to record a swift growth rate over the estimated time period. The Middle Eastern and African countries are expected to experience noticeable growth in the near future.

Some key players in the global insulin delivery devices market include Eli Lilly and Company, Medtronic plc., B. Braun Melsungen AG, Sanofi S.A., Novo Nordisk A/S, F. Hoffmann-La Roche Ltd., Biocon Ltd., Becton, Dickinson and Company, Valeritas, Inc., MannKind Corporation, and Insulet Corporation, among others.

Choose License Type

Request the coronavirus impact analysis across industries and markets

HappyClients

Office Address

Corporate Office

Zion Market Research 244 Fifth Avenue, Suite N202 New York, 10001, United States
Tel: +49-322 210 92714
USA/Canada Toll Free No.1-855-465-4651

Asia Pacific Office

3rd Floor, Mrunal Paradise, Opp Maharaja Hotel, Pimple Gurav, Pune 411061, Maharashtra, India
Phone No 020-46277770

Contact #

US OFFICE NO +1-386-310-3803
US/CAN TOLL FREE +1-855-465-4651
Email: sales@zionmarketresearch.com

We Are On Social